Novavax and Sanofi are marketing a Covid vaccine and developing combination doses

A health worker prepares a dose of the Novavax vaccine as the Dutch health service organization begins the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.

Patrick van Cutwijk | Getty Images

Novavax said on Friday it had signed on Multi-billion dollar deal With French pharmaceutical company Sanofi to co-market the company’s Covid vaccine starting next year and develop combination shots targeting coronavirus and influenza, among other efforts.

The licensing agreement will allow Novavax to lift its “persistence” warning, which it does first Issued In February 2023 due to doubts about its ability to continue operating, Novavax CEO John Jacobs told CNBC in an interview.

Leave a Reply

Your email address will not be published. Required fields are marked *